Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
20060303
DOI
10.1016/j.bmc.2009.12.055
PII: S0968-0896(09)01147-X
Knihovny.cz E-resources
- MeSH
- Antitubercular Agents chemistry pharmacology MeSH
- Cell Line MeSH
- Carbamates chemistry pharmacology MeSH
- Humans MeSH
- Mycobacterium tuberculosis drug effects MeSH
- Cell Proliferation drug effects MeSH
- Salicylanilides chemistry pharmacology MeSH
- Tuberculosis drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antitubercular Agents MeSH
- Carbamates MeSH
- salicylanilide MeSH Browser
- Salicylanilides MeSH
A series of 27 salicylanilide-based carbamates was prepared as a part of our ongoing search for new antituberculosis drugs. These compounds exhibited very good in vitro activity against Mycobacterium tuberculosis, Mycobacterium kansasii and Mycobacterium avium and, in particular, against five multidrug-resistant strains, with MIC values between 0.5-2 micromol/L. Moreover, they displayed moderate toxicity against intestinal cells with the selectivity index being up to 96. Furthermore, acid stability and a half-life of 43h at pH 7.4 were shown. Thus, these novel salicylanilide derivatives are drug candidates which should be seriously consider for further screening.
References provided by Crossref.org
Dibasic Derivatives of Phenylcarbamic Acid against Mycobacterial Strains: Old Drugs and New Tricks?
Antibacterial activity of salicylanilide 4-(trifluoromethyl)-benzoates
Antimycobacterial activity of salicylanilide benzenesulfonates
